NUKEM and Paul Scherrer Institute to Advance Nuclear Research and Collaboration NUKEM Technologies Engineering Services GmbH and the Paul Scherrer Institute (PSI), both ENS Corporate Members, have signed a Memorandum of Understanding (MoU) to strengthen collaboration in nuclear safety, science and technology. Both parties are committed to the highest safety standards for nuclear installations and stand…
PSI Developed A New Promising Radiopharmaceutical Successfully Tested A promising radiopharmaceutical against metastatic neuroendocrine tumours has been successfully tested for the first time in patients at the University Hospital Basel, Switzerland. The new radionuclide terbium-161 was developed at the Paul Scherrer Institute (PSI, ENS Corporate Member). This isotope has the property that when the radioisotope…
PSI Pioneers Proton Radiotherapy To Treat A Rare Type of Cancer Paul Scherrer Institute (PSI, ENS Corporate Member) and the University Hospital Zurich treated for the first time in Switzerland a patient affected by an oesophageal tumour by using proton radiotherapy. This research is part of the pan-European PROTECT trial (PROton versus photon Therapy for…
PSI Leads New Research To Fight Metastatic Prostate Cancer Researchers at the Paul Scherrer Institute (ENS Corporate Member, PSI) are developing a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug, studied by a research consortium involving PSI, the University Hospital Basel and ETH Zurich, is now being…
New PSI Study For More Detailed Tests Of Nuclear Fuel Cladding Recent micro-beam measurements at the Swiss Light Source SLS (Paul Scherrer Institut – PSI, ENS Corporate Member) have enabled insights into the crystal structure of hydrides that promote cracks in nuclear fuel cladding. This fundamental knowledge of the material properties of cladding will help…
The New PSI Pharmaceutical Laboratory Is Ready For Production Paul Scherrer Institut (PSI, ENS Corporate Member) announced that its new pharmaceutical laboratory for the manufacture of radiopharmaceuticals is ready for production, accordingly to the operating licence granted by the Swiss Agency for Therapeutic Products (Swissmedic). For more than 20 years, in collaboration with ETH Zurich,…
PSI New Method For Complex X-ray Studies Of Correlated Metals Researchers from the Paul Scherrer Institute PSI and the Brookhaven National Laboratory (BNL), working in an international team, have developed a new method for complex X-ray studies that will aid in better understanding so-called correlated metals. These materials could prove useful for practical applications in…
PSI New Method To Investigate Ageing Processes In Catalyst Materials Paul Scherrer Institute researchers have developed a new tomography method with which they can measure chemical properties inside catalyst materials in 3-D extremely precisely and faster than before. The application is equally important for science and industry, as researchers investigated the ageing process of the…
PSI Investigates For Suitable Swiss Deep Geological Repository Switzerland is planning to construct a deep geological repository for its radioactive waste by 2050. Three sites are currently under consideration and researchers at Paul Scherrer Institute are providing data that will help in determining which is most suitable. The search for suitable locations is being conducted…
PSI Aim at Extending Standard Model of Elementary Particle Physic With the high-intensity proton accelerator HIPA, the Paul Scherrer Institute generates elementary particles to clarify a fundamental question: How is our universe structured? With the help of pions, muons, and neutrons, the PSI researchers are conducting experiments to find out how the well established yet…